ドキソルビシンの世界市場レポート 2025年

ドキソルビシン市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.1％で18億7,000万米ドルに成長します。予測期間の成長は、個別化医療の進歩、標的ドラッグデリバリーシステム、免疫療法の組み合わせ、ゲノムおよびバイオマーカー調査、精密腫瘍学の成長に起因しています。予測期間の主な動向には、ナノテクノロジーの統合、併用療法、バイオシミラー市場の拡大、補助療法の重点化、心保護介入などがあります。

がんの有病率の上昇がドキソルビシン市場を推進しています。がんには、細胞の異常で制御不能な増殖を特徴とするさまざまな疾患が含まれます。ドキソルビシンは化学療法に広く使用されている抗生物質で、がん細胞のDNAを損傷することで増殖を抑制し、様々ながんと闘うのに役立ちます。がんの発生率の増加により、ドキソルビシンの需要が高まっています。例えば、世界保健機関（WHO）の報告によると、2022年には世界で約2,000万人のがん患者が新たに発生し、970万人が死亡しました。約5,350万人が診断から5年後の生活を送っており、およそ5人に1人が一生のうちにがんを発症し、男性の約9人に1人、女性の約12人に1人がこの病気で死亡しています。その結果、がん患者の増加がドキソルビシンの需要を牽引しています。

遺伝性疾患の増加は、今後のドキソルビシン市場の成長を促進すると予想されます。新生児スクリーニングは、特定の健康状態をチェックするために出生直後に実施される身体検査であり、これによりヘルスケア専門家は、病気を引き起こす前に特定のニーズを特定して対処することができます。このスクリーニングは、乳がんや卵巣がんを発症するリスクの高い乳幼児を特定するのに役立ち、ドキソルビシンを用いた早期の予防措置を可能にします。例えば、2022年にテキサス州保健局は、およそ394,000人の乳児がスクリーニングを受け、1,130人が新生児スクリーニング疾患のいずれかに罹患していることが判明したと報告しています。したがって、遺伝性疾患の増加がドキソルビシン市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ドキソルビシンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のドキソルビシン市場：成長率分析
• 世界のドキソルビシン市場の実績：規模と成長, 2019-2024
• 世界のドキソルビシン市場の予測：規模と成長, 2024-2029, 2034F
• 世界ドキソルビシン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のドキソルビシン市場薬剤処方別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 凍結乾燥粉末
• ドキソルビシンインジェクション
• 世界のドキソルビシン市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 腎臓がん
• 肝臓がん
• 肉腫
• 卵巣がん
• 肺がん
• 白血病
• 多発性骨髄腫
• その他の用途
• 世界のドキソルビシン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のドキソルビシン市場凍結乾燥粉末の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 再構成製剤
• フリーズドライ製剤
• 世界のドキソルビシン市場、ドキソルビシンインジェクションのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• すぐに使えるソリューション
• 希釈用濃縮溶液
• リポソームドキソルビシン注射

第7章 地域別・国別分析

• 世界のドキソルビシン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のドキソルビシン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ドキソルビシン市場：競合情勢
• ドキソルビシン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Cipla Limited
• Hikma Pharmaceuticals
• Mylan Pharmaceuticals Inc.
• Accord Healthcare Ltd.
• TTY Biopharm Company Limited
• Cadila Pharmaceuticals
• Neon Laboratories Limited
• APP Pharmaceuticals Manufacturing LLC
• Sun Pharmaceutical Industries Ltd.
• Transo-Pharm Handels GmbH
• LGM Pharma
• Zhejiang Hisun Pharma
• Actavis Pharma
• Celon Laboratories Limited
• Samarth Life Sciences Pvt. Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ドキソルビシン市場2029：新たな機会を提供する国
• ドキソルビシン市場2029：新たな機会を提供するセグメント
• ドキソルビシン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Doxorubicin is an anthracycline antibiotic used in cancer therapy due to its strong antitumor effects. It treats various cancers, including breast cancer, lung cancer, and hematological malignancies. The drug works by inhibiting DNA replication, which prevents cancer cells from dividing and growing.

Doxorubicin is available in two main forms lyophilized powder and doxorubicin injection. Lyophilized doxorubicin powder denotes a freeze-dried version of the chemotherapy drug, where the water content has been removed. Lyophilization is utilized to enhance preservation, ensuring the drug's stability and longevity. These formulations find application in the treatment of breast cancer, kidney cancer, liver cancer, sarcoma, ovarian cancer, lung cancer, leukemia, multiple myeloma, among others, and are accessible through hospital pharmacies, retail pharmacies, and online pharmacies.

The doxorubicin market research report is one of a series of new reports from The Business Research Company that provides doxorubicin market statistics, including the doxorubicin industry's global market size, regional shares, competitors with a doxorubicin market share, detailed doxorubicin market segments, market trends, and opportunities, and any further data you may need to thrive in the doxorubicin industry. This doxorubicin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The doxorubicin market size has grown strongly in recent years. It will grow from $1.33 billion in 2024 to $1.42 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to chemotherapy advancements, oncology treatment standard, clinical efficacy, patient survival rates, physician recommendations

The doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.87 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to personalized medicine advancements, targeted drug delivery systems, immunotherapy combinations, genomic and biomarker research, precision oncology growth. Major trends in the forecast period include nanotechnology integration, combination therapies, biosimilar market expansion, adjuvant therapy focus, cardioprotective interventions.

The rising prevalence of cancer is propelling the doxorubicin market. Cancer encompasses a range of diseases characterized by the abnormal and uncontrolled growth of cells. Doxorubicin is a widely used antibiotic in chemotherapy that helps combat various cancers by damaging the DNA of cancer cells, thereby inhibiting their growth. The increasing incidence of cancer has led to a greater demand for doxorubicin. For example, the World Health Organization reported that in 2022, there were approximately 20 million new cancer cases and 9.7 million deaths worldwide. About 53.5 million people were living five years post-diagnosis, and roughly 1 in 5 individuals will develop cancer in their lifetime, with around 1 in 9 men and 1 in 12 women dying from the disease. Consequently, the growing number of cancer patients is driving the demand for doxorubicin.

The increase in genetic disorders is expected to drive the growth of the doxorubicin market in the future. Newborn screening is a physical examination conducted shortly after birth to check for specific health conditions, enabling healthcare professionals to identify and address particular needs before they cause illness. This screening can help identify infants at high risk for developing breast and ovarian cancer, allowing for early preventive measures using doxorubicin. For example, in 2022, the Texas Department of State Health Services reported that approximately 394,000 babies were screened, with 1,130 found to be affected by one of the newborn screening disorders. Therefore, the rise in genetic disorders is contributing to the growth of the doxorubicin market.

Major companies in the doxorubicin market are focused on developing innovative products, including chemotherapy medications, to improve treatment efficacy and minimize side effects for cancer patients. Chemotherapy drugs work by targeting and killing rapidly dividing cancer cells, but they can also affect some healthy cells, resulting in side effects. Recent advancements aim to enhance specificity and reduce these adverse effects. For example, in August 2024, Lupin Limited, an India-based pharmaceutical company, launched Doxorubicin Hydrochloride Liposome Injection. This injection is used to treat advanced ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. Its liposomal formulation enables targeted delivery, which helps reduce systemic side effects and improve patient tolerance. This approach enhances treatment efficacy, making it a vital option in oncology therapies.

Major players in the doxorubicin market are strategically focusing on innovative drug development to enhance their market standing. Notably, in May 2023, Dr. Reddy's Laboratories, an India-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for the launch of Doxorubicin Hydrochloride Liposome Injection in the US market. This treatment targets ovarian and breast cancer, providing patients with a new therapeutic option. The approval process involved pre-clinical studies, clinical trials, and the submission of a New Drug Application (NDA) to the FDA to demonstrate the drug's safety and efficacy.

In March 2024, Johnson & Johnson, a US-based company engaged in the research, development, manufacturing, and sale of a diverse range of pharmaceutical products and medical devices, acquired Ambrx Biopharma, Inc. for $2 billion. This acquisition enhances Johnson & Johnson's capabilities in developing next-generation antibody-drug conjugates (ADCs), with a particular emphasis on targeting prostate cancer, an area of significant interest for the company. Ambrx Biopharma specializes in creating advanced ADCs for various cancer indications.

Major companies operating in the doxorubicin market include Pfizer Inc., Johnson and Johnson, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals, Mylan Pharmaceuticals Inc., Accord Healthcare Ltd., TTY Biopharm Company Limited, Cadila Pharmaceuticals, Neon Laboratories Limited, APP Pharmaceuticals Manufacturing LLC, Sun Pharmaceutical Industries Ltd., Transo-Pharm Handels GmbH, LGM Pharma, Zhejiang Hisun Pharma, Actavis Pharma, Celon Laboratories Limited, Samarth Life Sciences Pvt. Ltd

North America was the largest region in the doxorubicin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the doxorubicin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The doxorubicin market consists of sales of doxorubicin hydrochloride injections, adriamycin, doxil, myocet. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Doxorubicin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on doxorubicin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for doxorubicin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The doxorubicin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Formulation: Lyophilized Powder; Doxorubicin Injection
• 2) By Application: Breast Cancer; Kidney Cancer; Liver Cancer; Sarcoma; Ovarian Cancer; Lung Cancer; Leukemia; Multiple Myeloma; Other Applications
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Lyophilized Powder: Reconstituted Formulations; Freeze-Dried Preparations
• 2) By Doxorubicin Injection: Ready-To-Use Solutions; Concentrated Solutions For Dilution; Liposomal Doxorubicin Injections
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Doxorubicin Market Characteristics

3. Doxorubicin Market Trends And Strategies

4. Doxorubicin Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Doxorubicin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Doxorubicin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Doxorubicin Market Growth Rate Analysis
• 5.4. Global Doxorubicin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Doxorubicin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Doxorubicin Total Addressable Market (TAM)

6. Doxorubicin Market Segmentation

• 6.1. Global Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lyophilized Powder
• Doxorubicin Injection
• 6.2. Global Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Kidney Cancer
• Liver Cancer
• Sarcoma
• Ovarian Cancer
• Lung Cancer
• Leukemia
• Multiple Myeloma
• Other Applications
• 6.3. Global Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Doxorubicin Market, Sub-Segmentation Of Lyophilized Powder, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reconstituted Formulations
• Freeze-Dried Preparations
• 6.5. Global Doxorubicin Market, Sub-Segmentation Of Doxorubicin Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ready-To-Use Solutions
• Concentrated Solutions For Dilution
• Liposomal Doxorubicin Injections

7. Doxorubicin Market Regional And Country Analysis

• 7.1. Global Doxorubicin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Doxorubicin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Doxorubicin Market

• 8.1. Asia-Pacific Doxorubicin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Doxorubicin Market

• 9.1. China Doxorubicin Market Overview
• 9.2. China Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Doxorubicin Market

• 10.1. India Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Doxorubicin Market

• 11.1. Japan Doxorubicin Market Overview
• 11.2. Japan Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Doxorubicin Market

• 12.1. Australia Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Doxorubicin Market

• 13.1. Indonesia Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Doxorubicin Market

• 14.1. South Korea Doxorubicin Market Overview
• 14.2. South Korea Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Doxorubicin Market

• 15.1. Western Europe Doxorubicin Market Overview
• 15.2. Western Europe Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Doxorubicin Market

• 16.1. UK Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Doxorubicin Market

• 17.1. Germany Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Doxorubicin Market

• 18.1. France Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Doxorubicin Market

• 19.1. Italy Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Doxorubicin Market

• 20.1. Spain Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Doxorubicin Market

• 21.1. Eastern Europe Doxorubicin Market Overview
• 21.2. Eastern Europe Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Doxorubicin Market

• 22.1. Russia Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Doxorubicin Market

• 23.1. North America Doxorubicin Market Overview
• 23.2. North America Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Doxorubicin Market

• 24.1. USA Doxorubicin Market Overview
• 24.2. USA Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Doxorubicin Market

• 25.1. Canada Doxorubicin Market Overview
• 25.2. Canada Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Doxorubicin Market

• 26.1. South America Doxorubicin Market Overview
• 26.2. South America Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Doxorubicin Market

• 27.1. Brazil Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Doxorubicin Market

• 28.1. Middle East Doxorubicin Market Overview
• 28.2. Middle East Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Doxorubicin Market

• 29.1. Africa Doxorubicin Market Overview
• 29.2. Africa Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Doxorubicin Market Competitive Landscape And Company Profiles

• 30.1. Doxorubicin Market Competitive Landscape
• 30.2. Doxorubicin Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Doxorubicin Market Other Major And Innovative Companies

• 31.1. Cipla Limited
• 31.2. Hikma Pharmaceuticals
• 31.3. Mylan Pharmaceuticals Inc.
• 31.4. Accord Healthcare Ltd.
• 31.5. TTY Biopharm Company Limited
• 31.6. Cadila Pharmaceuticals
• 31.7. Neon Laboratories Limited
• 31.8. APP Pharmaceuticals Manufacturing LLC
• 31.9. Sun Pharmaceutical Industries Ltd.
• 31.10. Transo-Pharm Handels GmbH
• 31.11. LGM Pharma
• 31.12. Zhejiang Hisun Pharma
• 31.13. Actavis Pharma
• 31.14. Celon Laboratories Limited
• 31.15. Samarth Life Sciences Pvt. Ltd

32. Global Doxorubicin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Doxorubicin Market

34. Recent Developments In The Doxorubicin Market

35. Doxorubicin Market High Potential Countries, Segments and Strategies

• 35.1 Doxorubicin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Doxorubicin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Doxorubicin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer